Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 24, 2011

View Archived Issues

Clinical findings presented for sirukumab in lupus and rheumatoid arthritis

New mechanism explored for treating Alzheimer's disease

New LXR agonist displays promising antiatherosclerotic effects in vivo

Korean investigators discover new biomarker of disease activity in rheumatoid arthritis

Results reported from phase I trial of enavatuzumab in advanced solid tumors

Updated results presented from ongoing first-in-patient trial of PF-04691502

Amgen tests antibody-drug conjugate targeting EGFRvIII

New compounds for bone disorders prepared by Daiichi Sankyo

Astellas Pharma prepares novel NPT-IIb inhibitors

FDA approves Medtronic's iPro2 professional CGM system

Novel tyrosine-protein kinase SYK inhibitors designed by GSK

Transition Therapeutics set to close USD 5 million private placement

UCB decides on option agreement to license SYN-118

Japanese researchers synthesize new PDE4B inhibitors

Takeda Pharmaceuticals reports novel acetyl-CoA carboxylase inhibitors

Advaxis completes pre-IND meeting for ADXS-HER2

Neuralstem injects first patient with stem cells in cervical region of spine

Takeda files NDA for fixed-dose tablet of alogliptin/metformin

FDA approves Transcept's insomnia drug Intermezzo

Mesoblast and FDA agree on adult stem cell trial in type 2 diabetes

Summit's SMT-C1100 granted orphan drug status in Duchenne's muscular dystrophy

Phase II trial of RP-G28 in lactose intolerance completed

Aeterna Zentaris licenses anticancer agent to Hikma

Cipher submits amendment to NDA for novel acne treatment

NICE decides not to recommend Lucentis for treatment of macular edema

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 5, 2026.
Cancer specter looming, Abtect effect in UC wallops Abivax
BioWorld
Although analysts liked the data – calling them “truly amazing” and “transformational” – Wall Street apparently had qualms about three cancer cases that turned up...
FB-7033 demonstrates efficacy in MASH management
BioWorld Science
17-β-Hydroxysteroid dehydrogenase 13 (HSD17B13) and lipid transferase CIDEB are known to contribute to metabolic dysfunction-associated steatohepatitis (MASH)...
Preclinical results support Actinium’s radioconjugate ATNM‑400 for NSCLC
BioWorld Science
At the recent meeting of the Society of Nuclear Medicine and Molecular Imaging, researchers from Actinium Pharmaceuticals Inc. presented preclinical efficacy data...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...